FCCC LOGO Faculty Publications
Grivas P , Plimack ER , Balar AV , Castellano D , O'Donnell PH , Bellmunt J , Powles T , Hahn NM , de Wit R , Bajorin DF , Ellison MC , Frenkl TL , Godwin JL , Vuky J
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Eur Urol Oncol. 2020 jun;3(3) :351-359
Back to previous list
BACKGROUND: Patients with treatment-naive advanced urothelial cancer (UC) ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. OBJECTIVE: To evaluate the safety and antitumor activity of first-line pembrolizumab in subgroups of cisplatin-ineligible older patients (aged >/=65 and >/=75 yr) with advanced UC in KEYNOTE-052 (NCT02335424), including those with poor performance status (Eastern Cooperative Oncology Group performance status score 2 [ECOG PS2]). DESIGN, SETTING, AND PARTICIPANTS: Patients were cisplatin ineligible, had treatment-naive, histologically/cytologically confirmed, locally advanced/metastatic UC with measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1]), and had ECOG PS0-2. Patient subgroups analyzed were aged >/=65yr (n = 302), >/=75 yr (n = 179), >/=65yr with ECOG PS2 (>/=65yr+ECOG PS2; n = 119), and >/=75 yr+ECOG PS2 (n = 78). INTERVENTION: All patients received pembrolizumab 200mg intravenously every 3 wk until confirmed progression, intolerable toxicity, patient withdrawal, or 24 mo of therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was objective response rate (ORR) as per RECIST v1.1. The key secondary endpoints were overall survival (OS), duration of response (DOR), and safety. RESULTS AND LIMITATIONS: ORRs for the >/=65yr, >/=75 yr, >/=65yr+ECOG PS2, and >/=75 yr+ECOG PS2 subgroups were 29%, 27%, 29%, and 31%, respectively; rates of complete and partial responses were similar across subgroups (9%, 5%, 6%, and 6%, and 20%, 22%, 23%, and 24%, respectively). Median DOR and OS were also consistent across the >/=65yr and >/=65yr+ECOG PS2 subgroups and the >/=75 yr and >/=75 yr+ECOG PS2 subgroups. Study limitations included open-label design, lack of a comparator group, and nature of post hoc exploratory analysis. CONCLUSIONS: The clinical benefit of pembrolizumab in advanced UC appeared to be consistent regardless of age and/or poor performance status. PATIENT SUMMARY: This study looked at whether older age and poorer performance status affect how well patients with previously untreated advanced urothelial cancer ineligible for standard-of-care treatment respond to pembrolizumab. Outcomes with pembrolizumab were not affected by older age or poorer performance status, making it an effective option.
2588-9311 Grivas, Petros Plimack, Elizabeth R Balar, Arjun V Castellano, Daniel O'Donnell, Peter H Bellmunt, Joaquim Powles, Thomas Hahn, Noah M de Wit, Ronald Bajorin, Dean F Ellison, Misoo C Frenkl, Tara L Godwin, James L Vuky, Jacqueline Journal Article Netherlands Eur Urol Oncol. 2020 May 15. pii: S2588-9311(20)30034-1. doi: 10.1016/j.euo.2020.02.009.